Related Experiment Videos
Hepatic failure associated with imipramine therapy
Pharmacopsychiatry
|March 1, 1996
Abstract:
Imipramine is an antidepressant drug that is rarely associated with mild liver function abnormalities. These are usually minor and transient liver enzyme elevations which return to normal levels upon discontinuation of the drug. We describe a 48-year-old male who developed subfulminant hepatic failure after imipramine usage, with complete recovery within three months after discontinuation of the drug.
Insights
Imipramine, an antidepressant, can rarely cause liver issues. This case shows a rare instance of severe liver injury from imipramine, with full recovery after stopping the medication.
Area of Science:
- Hepatology
- Clinical Pharmacology
- Toxicology
Background:
- Imipramine is a tricyclic antidepressant.
- Antidepressants can cause liver function abnormalities.
- These abnormalities are typically mild and transient.
Observation:
- A 48-year-old male patient presented with severe liver injury.
- The patient had a history of imipramine usage.
- The liver injury was characterized as subfulminant hepatic failure.
Findings:
- Imipramine use was linked to the development of subfulminant hepatic failure.
- Discontinuation of imipramine led to complete recovery.
- Full recovery occurred within three months of drug cessation.
Implications:
- This case highlights a rare but severe adverse effect of imipramine.
- Clinicians should monitor liver function in patients taking imipramine.
- Early recognition and drug discontinuation are crucial for managing imipramine-induced liver injury.